Risankizumab was noninferior to ustekinumab with respect to clinical remission at Week 24, and superior with respect to endoscopic remission at Week 48. This study aimed to present data from SEQUENCE, a direct head-to-head trial assessing the efficacy and safety of risankizumab vs ustekinumab in patients with moderate-to-severe CD, in whom at least one anti-TNF treatment had failed.

Additionally, no new safety risks were identified in association with risankizumab in this trial.

Keywords:


Publication thumbnail: Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease
LinkedIn